The SCOPE Summit 2026, held in Orlando, Florida, from February 2 to 5, 2026, highlighted the dominance of small- to mid-segment companies and specialized CROs focusing on specific therapy areas or aspects of clinical trials, such as bioanalysis. With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as a bellwether for clinical innovation. This year’s event showcased a notable presence of technology vendors focused on providing eClinical solutions, including risk-based quality management (RBQM), randomization and trial supply management (RTSM), eSourcing, and clinical trial supply chain and logistics solutions. The central theme was particularly noteworthy: AI adoption in clinical research has matured and digital protocols are now the backbone enabling it.

SCOPE 2026 stood out not only for the high level of participation but also for a distinct shift in tone. The industry is finally advancing beyond conceptual discussions about AI, data integration, and patient-centricity toward actual execution.

Throughout the various presentations, panel discussions, and plenary keynote sessions, five major themes emerged.
1.     Patient centricity
2.     AI taking center stage in clinical trials
3.     Digital protocols for clinical trial execution
4.     Connected clinical data systems
5.     Modernized site enablement

This analysis provides key insights from SCOPE 2026, showcasing the leading organizations advancing innovation across various segments of the clinical research industry.

Author: Aarti Siddhesh Chitale